Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Zacks Small-Cap Research 2026

Thursday, May 14, 2026 1 min read
Key Takeaway: Radiopharm Theranostics has announced the dosing of its first patient in a Phase 1/2a clinical study for BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate this therapeutic study targeting B7H3. Additionally, positive updates were shared regarding four of its clinical programs.
Price reaction · baseline $4.78 (2026-05-14T16:17:00.000Z) · hit during market hours · clean, no other RADX news in the window
day 0 close · peak
-1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • The company received IND approval from the US FDA.
  • Positive updates were provided across four clinical programs.

Full Press Release Details

• Analyst Reports
• PDF
• May 14, 2026
Loading Viewer…

More Announcements & Updates

• Announcements
• February 14, 2023
• Announcements
• October 18, 2023
• Announcements
• December 22, 2023
• Announcements
• November 29, 2021

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the BetaBart (RV-01) study about?

The BetaBart (RV-01) study is a Phase 1/2a clinical trial targeting B7H3.

When did Radiopharm Theranostics dose its first patient?

Radiopharm Theranostics dosed its first patient in the Phase 1/2a study recently.

What approval did Radiopharm receive from the FDA?

Radiopharm received IND approval from the US FDA to initiate the BetaBart study.

How many clinical programs received positive updates?

Radiopharm provided positive updates across four clinical programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a B7H3 FDA IND approval
Last updated: May 14, 2026